Biotech company MannKind (NASDAQ:56400P706) is developing a fast-acting, inhalable insulin drug called Afrezza. The drug has previously been rejected by the FDA, but the company looks determined to get this product to market. Today, MannKind announced that its two Phase 3 Afrezza clinical trials have completed patient enrollment, and this will help the company stay on track to file for FDA approval in Q3 of 2013. The company has shown interest in linking up with a larger company, but a partnership has been elusive. It could be that Pfizer's (NYSE:PFE) failed attempt to market Nektar Therapeutic's (NASDAQ:NKTR) inhalable insulin product, Exubera, has made other big pharma companies hesitant to enter this market.
In the following video, healthcare analysts Max Macaluso and David Williamson explain this news, its impact on the company's share price, and discuss why MannKind still hasn't announced a partnership with any of the major pharmaceutical companies.
Biotech stocks can be some of the riskiest on the stock market, and can rapidly increase in value after positive clinical trial results --- or crash in the face of bad news. However, biotech is not the only technology investors can profit from. The Motley Fool's new report The Only Stock You Need To Profit From the NEW Technology Revolution highlights a company recommended by Fool analysts that still has plenty of room left to grow. To get instant access to the name of this company transforming the IT industry, click here -- it's free.
Max Macaluso has no positions in the stocks mentioned above. David Williamson owns shares of Pfizer, but he holds no other position in any company mentioned. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend MannKind. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.